Archives of Virology

, Volume 162, Issue 1, pp 165–169 | Cite as

Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV

  • Caroline Furtado Noble
  • Fernanda MaltaEmail author
  • Gaspar Lisboa-Neto
  • Michele Soares Gomes-Gouvêa
  • Andrea Gurgel Batista Leite
  • Vanessa Fusco Duarte de Castro
  • Rubia Anita Ferraz Santana
  • Flair José Carrilho
  • Maria Cássia Mendes-Correa
  • João Renato Rebello Pinho
Original Article


Resistance-associated variants (RAVs) represent a challenge to the success of new HCV therapies. The aim of this study was to describe the prevalence of naturally occurring NS5B RAVs in Brazilian direct acting antivirals (DAA)-naïve patients infected with HCV genotype 1, or co-infected with HIV. Patient enrollment and sample collection were performed between 2011 and 2013. Using Sanger-based sequencing, 244 sequences were obtained. RAVs detected in HCV-1a sequences were V321A (1.6 %), M414V (1.3 %), A421V (21.4-23.7 %), A421G (1.3 %) and Y448H (1.3 %); and in HCV-1b sequences were L159F (16.1 %), C316N (7.1-16.3 %) and A421V (3.2-6.3 %). Understanding the real RAVs scenario in patients is fundamental to establishing the most effective therapeutic strategy and in minimizing the risks for their selection.


Human Immunodeficiency Virus Sofosbuvir NS5B Region NS5A RAVs NS5B Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

This project was supported by grant 2011/50633-4 São Paulo Research Foundation (FAPESP) and Alves de Queiroz Family Fund for Research. João Renato Rebello Pinho and Maria Cassia Mendes Correa receive fellowships from CNPq (Bolsista de Produtividade). Caroline Furtado Noble is a graduate student from the Department of Gastroenterology at the University of São Paulo who received a fellowship from CAPEs.


  1. 1.
    Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRefPubMedGoogle Scholar
  2. 2.
    Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD (2009) Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 51:574–581CrossRefPubMedGoogle Scholar
  3. 3.
    Sulkowski MS, Thomas DL (2003) Hepatitis C in the HIV-infected patient. Clin Liver Dis 7:179–194CrossRefPubMedGoogle Scholar
  4. 4.
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study. Arch Intern Med 166:1632–1641CrossRefPubMedGoogle Scholar
  5. 5.
    Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57CrossRefPubMedGoogle Scholar
  6. 6.
    Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, Montarroyos UR, Braga C, Turchi MD, Coral G, Crespo D, Lima ML, Alencar LC, Costa M, dos Santos AA, Ximenes RA (2013) Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 13:60CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V, Pereira LM, Coelho HS, Silva AO, Fonseca JC, Rosa H, Lacet CM, Bernardini AP (2005) Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 38:41–49CrossRefPubMedGoogle Scholar
  8. 8.
    Rockstroh JK (2015) Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals. Liver Int 35(Suppl 1):51–55CrossRefPubMedGoogle Scholar
  9. 9.
    Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486–504CrossRefPubMedGoogle Scholar
  10. 10.
    Feld JJ (2014) Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 34:37–46CrossRefPubMedGoogle Scholar
  11. 11.
    Franco S, Casadella M, Noguera-Julian M, Clotet B, Tural C, Paredes R, Martinez MA (2013) No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing. J Clin Virol 58:726–729CrossRefPubMedGoogle Scholar
  12. 12.
    Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368:34–44CrossRefPubMedGoogle Scholar
  13. 13.
    Nguyen LT, Hall N, Sheerin D, Carr M, De Gascun CF (2016) Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther 21:447–453CrossRefPubMedGoogle Scholar
  14. 14.
    Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H (2014) Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59:1666–1674CrossRefPubMedGoogle Scholar
  15. 15.
    Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M (2009) Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49:1069–1082CrossRefPubMedGoogle Scholar
  16. 16.
    Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B (2013) A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 59:18–23CrossRefPubMedGoogle Scholar
  17. 17.
    Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK (2015) Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56–65CrossRefPubMedGoogle Scholar
  18. 18.
    Castilho MC, Martins AN, Horbach IS, Perez Rde M, Figueiredo FA, Pinto Pde T, Nabuco LC, Lima DB, Tanuri A, Porto LC, Ferreira Junior Oda C (2011) Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients. Mem Inst Oswaldo Cruz 106:968–975CrossRefPubMedGoogle Scholar
  19. 19.
    Hall T (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41:95–98Google Scholar
  20. 20.
    Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30:2725–2729CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V (2015) Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62:1623–1632CrossRefPubMedGoogle Scholar
  22. 22.
    Gamal N, Andreone P (2015) Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination. Drugs Today (Barc) 51:303–314CrossRefGoogle Scholar
  23. 23.
    McQuaid T, Savini C, Seyedkazemi S (2015) Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol 3:27–35CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lawitz E, Jacobson IM, Nelson DR, Zeuzem S, Sulkowski MS, Esteban R, Brainard D, McNally J, Symonds WT, McHutchison JG, Dieterich D, Gane E (2015) Development of sofosbuvir for the treatment of hepatitis C virus infection. Ann N Y Acad Sci 1358:56–67CrossRefPubMedGoogle Scholar
  25. 25.
    Pawlotsky JM (2015) Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology 148:468–479CrossRefPubMedGoogle Scholar
  26. 26.
    Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL (2005) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49:2059–2069CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Andre-Garnier E, Ribeyrol O, Gournay J, Besse B, Coste-Burel M, Mabille-Archambeaud I, Billaud E, Biron C, Pineau S, Raffi F, Imbert-Marcille BM (2016) Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort. Antivir Ther. doi: 10.3851/IMP3053 PubMedGoogle Scholar
  28. 28.
    Hedskog C, Dvory-Sobol H, Gontcharova V, Martin R, Ouyang W, Han B, Gane EJ, Brainard D, Hyland RH, Miller MD, Mo H, Svarovskaia E (2015) Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat 22:871–881CrossRefPubMedGoogle Scholar
  29. 29.
    Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H (2015) L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213:1240–1247CrossRefPubMedGoogle Scholar
  30. 30.
    Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N (2016) Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. Hepatol ResGoogle Scholar
  31. 31.
    Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA (2015) Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7:5206–5224CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL (2013) Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544–1553CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Halfon P, Sarrazin C (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 32(Suppl 1):79–87CrossRefPubMedGoogle Scholar
  34. 34.
    Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J (2009) Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5. Antivir Ther 14:723–730PubMedGoogle Scholar
  35. 35.
    Aissa Larousse J, Trimoulet P, Recordon-Pinson P, Papuchon J, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H (2014) Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol 86:1350–1359CrossRefPubMedGoogle Scholar
  36. 36.
    Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF (2016) Daclatasvir + asunaprevir + beclabuvir +/− ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int 36:189–197CrossRefPubMedGoogle Scholar
  37. 37.
    Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, Lopez-Labrador FX (2016) Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60:2402–2416CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Caroline Furtado Noble
    • 1
    • 2
  • Fernanda Malta
    • 1
    • 2
    Email author
  • Gaspar Lisboa-Neto
    • 3
  • Michele Soares Gomes-Gouvêa
    • 1
    • 2
  • Andrea Gurgel Batista Leite
    • 4
  • Vanessa Fusco Duarte de Castro
    • 5
  • Rubia Anita Ferraz Santana
    • 5
  • Flair José Carrilho
    • 2
  • Maria Cássia Mendes-Correa
    • 3
    • 6
  • João Renato Rebello Pinho
    • 1
    • 2
    • 5
  1. 1.Laboratory of Tropical Gastroenterology and Hepatology “João Alves de Queiroz and Castorina Bittencourt Alves”, LIM-07, Institute of Tropical MedicineUniversity of São PauloSão PauloBrazil
  2. 2.Department of Gastroenterology, School of MedicineUniversity of São PauloSão PauloBrazil
  3. 3.Department of Infectious and Parasitic Diseases, School of MedicineUniversity of São PauloSão PauloBrazil
  4. 4.Health CenterCaxias do SulBrazil
  5. 5.Hospital Israelita Albert EinsteinSão PauloBrazil
  6. 6.Laboratory of Virology, LIM-52, Institute of Tropical MedicineUniversity of São PauloSão PauloBrazil

Personalised recommendations